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ABSTRACT
Objective: To evaluate 5-year efficacy and safety of alemtuzumab in patients with active
relapsing-remitting multiple sclerosis and inadequate response to prior therapy.
Methods: In the 2-year Comparison of Alemtuzumab and Rebif Efficacy in Multiple Sclerosis
(CARE-MS) II study (NCT00548405), alemtuzumab-treated patients received 2 courses (base-
line and 12 months later). Patients could enter an extension (NCT00930553), with as-needed
alemtuzumab retreatment for relapse or MRI activity. Annualized relapse rate (ARR), 6-month
confirmed disability worsening (CDW; $1-point Expanded Disability Status Scale [EDSS] score
increase [$1.5 if baseline EDSS 5 0]), 6-month confirmed disability improvement (CDI; $1-point
EDSS decrease [baseline score $2.0]), no evidence of disease activity (NEDA), brain volume loss
(BVL), and adverse events (AEs) were assessed.
Results: Most alemtuzumab-treated patients (92.9%) who completed CARE-MS II entered the
extension; 59.8% received no alemtuzumab retreatment. ARRwas low in each extension year (years
3–5: 0.22, 0.23, 0.18). Through 5 years, 75.1% of patients were free of 6-month CDW; 42.9%
achieved 6-month CDI. In years 3, 4, and 5, proportions with NEDA were 52.9%, 54.2%, and
58.2%, respectively. Median yearly BVL remained low in the extension (years 1–5: 20.48%,
20.22%, 20.10%, 20.19%, 20.07%). AE exposure-adjusted incidence rates in the extension
were lower than in the core study. Thyroid disorders peaked at year 3, declining thereafter.
Conclusions: Alemtuzumab provides durable efficacy through 5 years in patients with an inade-
quate response to prior therapy in the absence of continuous treatment.
Classification of evidence: This study provides Class III evidence that alemtuzumab provides effi-
cacy and slowing of brain atrophy through 5 years. Neurology® 2017;89:1117–1126
GLOSSARY
AE5 adverse event;ARR5 annualized relapse rate;BPF5 brain parenchymal fraction;BVL5 brain volume loss;CARE-MS II5
Comparison of Alemtuzumab and Rebif Efficacy in Multiple Sclerosis II; CDI 5 confirmed disability improvement; CDW 5 con-
firmed disability worsening; CI 5 confidence interval; DMT 5 disease-modifying therapy; EAIR 5 exposure-adjusted incidence
rate; EDSS 5 Expanded Disability Status Scale; Gd 5 gadolinium; IAR 5 infusion-associated reaction; IFN-b-1a 5 interferon
b-1a; ITP 5 immune thrombocytopenia; MS 5 multiple sclerosis; NEDA 5 no evidence of disease activity; RRMS 5 relapsing-
remitting multiple sclerosis; SC 5 subcutaneous.
Alemtuzumab (LEMTRADA; Sanofi Genzyme, Cambridge, MA) is a humanized monoclonal
antibody that depletes circulating lymphocytes by selectively targeting CD52, which is expressed
at high levels on T and B lymphocytes. Depletion is followed by a characteristic pattern of
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lymphocyte repopulation and a cytokine
expression shift toward a less inflammatory
profile, both of which may contribute to dura-
ble efficacy.1,2 Currently, alemtuzumab is
approved in over 60 countries for treatment
of adults with relapsing-remitting multiple
sclerosis (RRMS); in the European Union, it
is approved for adults with active RRMS
defined by clinical or imaging features, includ-
ing treatment-naive patients, and, in the
United States, it is generally reserved for pa-
tients who have had inadequate response to at
least 2 drugs indicated for MS treatment.3–5
Efficacy and safety of alemtuzumab in pa-
tients with RRMS were evaluated in 3 rater-
blinded clinical trials. In the phase 2
CAMMS223 (NCT00050778)6 and the
phase 3 Comparison of Alemtuzumab and
Rebif Efficacy in Multiple Sclerosis I
(CARE-MS I [NCT00530348])7 studies of
treatment-naive patients, and the CARE-
MS II (NCT00548405)8 trial of those with
an inadequate response to prior therapy,
alemtuzumab treatment was superior to sub-
cutaneous interferon b-1a (SC IFN-b-1a;
Rebif; EMD Serono Inc., Rockland, MA)
on clinical and MRI outcomes. Significantly
more alemtuzumab-treated patients
achieved no evidence of disease activity
(NEDA) in the 2-year, phase 3 studies,7,8
and brain volume loss (BVL) was signifi-
cantly reduced with alemtuzumab in all 3
trials.6–8 The most frequent adverse events
(AEs) with alemtuzumab were infusion-
associated reactions (IARs); treatment-
associated autoimmune AEs were also
observed.6–8 These trials demonstrated a pos-
itive benefit–risk profile of alemtuzumab.
This report presents interim efficacy and
safety results through 3 years of an extension
study (NCT00930553) in patients who
received alemtuzumab during the core
CARE-MS II trial (total of 5 years of
follow-up).
METHODS Patients and procedures for the CARE-MS
II core study. The design of the 2-year core study has been
published previously.8 Briefly, CARE-MS II was a randomized,
rater-blinded, active-controlled, head-to-head trial comparing
alemtuzumab 12 mg and SC IFN-b-1a (44 mg 3 times per
week) in patients with active disease ($2 relapses in the pre-
vious 2 years and $1 relapse in the prior year) and inadequate
response to prior therapy ($1 relapse while receiving IFN-b or
glatiramer acetate after $6 months of treatment). Randomi-
zation into a third treatment arm (alemtuzumab 24 mg) was
discontinued early and deemed exploratory for statistical pur-
poses. Safety data from the 24-mg arm are summarized in this
report.
Procedures for the extension study. Alemtuzumab-treated
patients who completed CARE-MS II could enroll in the
extension and receive, at the investigator’s discretion, additional
alemtuzumab courses (12 mg on 3 consecutive days) $48
weeks after the most recent course, if they had evidence of MS
disease activity ($1 protocol-defined relapse or $2 new/
enlarging T2 hyperintense or gadolinium [Gd]-enhancing brain
or spinal cord lesions on MRI). Retreatment-disqualifying cri-
teria included, but were not limited to, pregnancy and diagnosis
of immune thrombocytopenia (ITP) or other immune cytope-
nia. Decisions on whether to initiate retreatment in eligible
patients, or to provide another licensed disease-modifying
therapy (DMT), were left to the treating physicians and pa-
tients. Patients who received SC IFN-b-1a for 2 years in the
core study could also enroll in the extension and switch to
alemtuzumab treatment; results for these patients will be re-
ported separately.
Efficacy assessments. The Expanded Disability Status Scale
(EDSS) was assessed by raters blinded throughout the exten-
sion to core study treatment assignment and treatment history.
EDSS was assessed quarterly and for evaluation of suspected
relapses. Relapse events required objective signs on examina-
tion, lasting $48 hours, and were confirmed by the investiga-
tor. Annual MRI scans were analyzed by blinded imaging
specialists at NeuroRx Research (Montréal, Canada [lesion-
based analyses]) and the Cleveland Clinic MS MRI Analysis
Center (Cleveland, OH [brain parenchymal fraction (BPF)
analysis]).
Clinical efficacy endpoints included annualized relapse
rate (ARR); proportion of relapse-free patients; 6-month con-
firmed disability worsening (CDW; $1.0-point EDSS score
increase from core study baseline [$1.5 if baseline EDSS score
5 0]); mean change from baseline EDSS score; proportions of
patients with improved ($1.0-point decrease), worsened
($1.0-point increase), or stable (#0.5-point change) EDSS
scores compared with baseline; and 3-, 6-, or 12-month con-
firmed disability improvement (CDI; $1.0-point decrease
from core study baseline EDSS score, in patients with baseline
EDSS scores $2.0).
MRI lesion assessments included proportions of patients with
Gd-enhancing, new/enlarging T2 hyperintense, and new nonen-
hancing T1 hypointense lesions. Median percentage BVL from
baseline and per year was calculated.
Absence of clinical disease activity (absence of both relapses
and 6-month CDW), absence of MRI lesion activity (absence
of both new Gd-enhancing and new/enlarging T2 hyperintense
lesions), and NEDA (absence of both clinical and MRI lesion
activity) were assessed annually and cumulatively (sustained over
years 3–5).
Safety monitoring. AEs, serious AEs, medical events of interest,
and laboratory tests for thyroid function (at least quarterly),
hematology (at least monthly), serum creatinine (monthly), and
urinalysis with microscopy (monthly) were evaluated. All safety
monitoring procedures continued until 4 years after last alemtu-
zumab administration, or until study end, whichever occurred
later. IARs were defined as any AE with onset during infusion
or #24 hours postinfusion.
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Classification of evidence. We examined efficacy and safety
with alemtuzumab through 5 years. This study provides Class
III evidence that efficacy outcomes were maintained or further
improved with alemtuzumab during extended follow-up in
patients with active RRMS who had an inadequate response to
prior therapy. Durable efficacy without continuous treatment was
shown using several assessments including ARR, CDW, CDI,
MRI lesion outcomes, NEDA, and slowing of BVL; most
Figure 1 Patient disposition
The disposition schematic includes participation of patients treated with alemtuzumab 12 mg in the core CARE-MS II and then enrolled in the long-term
extension study. *The as-treated population (n5 435) consisted of 426 patients originally randomized to alemtuzumab 12 mg and an additional 9 patients
who were randomized to alemtuzumab 24 mg but who instead received alemtuzumab 12 mg/d in the core study. **Neither death that occurred in the core
study was related to treatment. CARE-MS 5 Comparison of Alemtuzumab and Rebif Efficacy in Multiple Sclerosis; DMT 5 disease-modifying therapy.
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Figure 2 Clinical efficacy and disease activity outcomes over 5 years in alemtuzumab patients
(A) ARR over 5 years. Results are shown for patients who received alemtuzumab 12 mg in the core CARE-MS II study and enrolled in the extension. A post
hoc analysis revealed a statistically significant difference between the ARR in year 5 and the ARR in years 0–2 (p 5 0.0021), and no significant difference
between ARRs in either year 3 or year 4 and the ARR in years 0–2. (B) Percentage of patients with improved ($1.0-point decrease), stable (#0.5-point
change), or worsened ($1.0-point increase) EDSS scores at year 5 of the extension study compared with core study baseline. Analyses are shown for all
patients who received alemtuzumab 12 mg in the core study and enrolled in the extension. (C) Percentage of patients with 3-, 6-, or 12-month CDI over 5
years. Kaplan-Meier analysis of time to 3-, 6-, or 12-month CDI is shown for patients who received alemtuzumab 12 mg in the core CARE-MS II study and
enrolled in the extension. (D) Proportion of patients with NEDA over 5 years. NEDA outcomes are shown for patients who received alemtuzumab 12mg in the
core CARE-MS II study and enrolled in the extension. *Baseline percentage of patients free of gadolinium (Gd)–enhancing lesions: 58%. ARR 5 annualized
relapse rate; CARE-MS5 Comparison of Alemtuzumab and Rebif Efficacy in Multiple Sclerosis; CDI5 confirmed disability improvement; CDW5 confirmed
disability worsening; CI 5 confidence interval; EDSS 5 Expanded Disability Status Scale; NEDA 5 no evidence of disease activity.
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(59.8%) patients received no alemtuzumab retreatment through
5 years.
Statistical analysis. Analyses were based on all available data
(without imputation) for alemtuzumab 12-mg patients through
5 years from first alemtuzumab dose in CARE-MS II, with
interim data cutoff of October 4, 2014.
ARR was estimated using negative binomial regression with
robust variance estimation and covariate adjustment for geo-
graphic region. Proportions of patients with 6-month CDW or
3-, 6-, or 12-month CDI were estimated by Kaplan-Meier
method. Percentages of patients with improved ($1.0-point
decrease), stable (#0.5-point change), or worsened ($1.0-point
increase) EDSS scores from baseline were reported.
Safety data were reported as incidences (percentage of pa-
tients with $1 event). Incidence rates adjusted for follow-up
time are also appropriate to be reported in trials with long-term
follow-up. Therefore, exposure-adjusted incidence rates
(EAIRs) per 100 patient-years ([number of patients with spe-
cific event divided by total annual exposure time among pa-
tients at risk of initial occurrence of event] 3 100) were also
reported in the time cohorts. EAIR is interpreted as number of
events occurring in the population per unit of time.9 Autoim-
mune AEs were reported using time of first AE occurrence over
total follow-up time (0–5 years).
Standard protocol approvals, registrations, and patient
consents. This trial is registered with ClinicalTrials.gov
(NCT00548405; NCT00930553). All procedures were
approved by local institutional ethics review boards of partici-
pating sites. Patients provided written informed consent.
RESULTS Patients. A total of 435 patients received
alemtuzumab 12 mg in CARE-MS II; of 423
alemtuzumab-treated patients who completed
CARE-MS II, 393 (92.9%) entered the extension, of
whom 357 (90.8%) remained on study at month 60
(year 5; figure 1). Baseline characteristics of CARE-
MS II patients have been reported previously.8
In CARE-MS II, alemtuzumab patients received
12 mg/d at baseline (5 consecutive days) and 12
months later (3 consecutive days). Of the 393 pa-
tients who entered the extension, 17 received another
DMT but no further alemtuzumab treatment during
the extension. Of the remaining 376 patients, 218
(58.0%) received just 2 courses of alemtuzumab, with
113 (30.1%), 39 (10.4%), and 6 (1.6%) patients
receiving 1, 2, or 3 additional courses, respectively,
of alemtuzumab (table e-1 at Neurology.org). Relapse
was the most common reason for alemtuzumab re-
treatment (61.0% of retreatment courses for which
a reason was provided); 16.1% of retreatments were
prompted by MRI lesion activity and 22.9% by com-
bined relapse and MRI lesion activity. Thirty patients
(7.6%) received $1 other DMT (dimethyl fumarate
[n5 5], fingolimod [5], glatiramer acetate [12], IFN-
b-1a [1], IFN-b-1b [3], natalizumab [4], rituximab
[4], or teriflunomide [3]); of these, 7 received more
than 1 DMT (2 DMTs: 6 patients; 3 DMTs: 1
patient). Thirteen (3.3%) patients received both
alemtuzumab retreatment and another DMT.
Efficacy. ARR remained lower during each extension
year and over years 3–5 than during the core study
(figure 2A). Mean EDSS scores remained stable, with
changes from core study baseline of 20.20, 20.06,
0.00, and 10.06 for years 2–5, respectively. Half of
patients (51.7%) had stable EDSS scores at year 5;
24.9% improved and 23.4% worsened (figure 2B).
From baseline to year 5, 75.1% (95% confidence
interval [CI] 70.5%–79.2%) of patients were free of
6-month CDW (i.e., 24.9% [20.8%–29.5%] expe-
rienced 6-month CDW), and 42.9% (95% CI
37.4%–48.9%) achieved 6-month CDI (figure 2C).
During each extension year, most alemtuzumab-
treated patients showed no clinical disease activity
or MRI lesion activity, and more than 50% attained
NEDA (figure 2D). Cumulatively in years 3–5,
51.8% were free of clinical disease activity, 48.6%
showed no MRI lesion activity, and 27.0% showed
neither clinical disease nor MRI lesion activity.
Through each extension year, most patients were free
of new Gd-enhancing or new/enlarging T2
Figure 3 Brain volume loss over 5 years
Median percentage yearly change in brain parenchymal fraction (BPF). Results are shown for
patients who received alemtuzumab 12 mg in the core study and enrolled in the extension.
CI 5 confidence interval.
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hyperintense lesions (figure 2D) and new T1 hypo-
intense lesions (year 3, 87.5%; year 4, 86.3%; year 5,
87.5%).
Yearly BVL rate continued to decrease in year 3
compared with the core study, remaining low in years
4 and 5 (figure 3). Median BPF change from baseline
to year 5 was 20.855%.
In the cohort of patients who achieved NEDA at
year 2 and received no additional treatment (i.e., no
alemtuzumab retreatment since the initial 2 courses
and no other DMT [n 5 141]; figure e-1A), most
patients achieved NEDA in each extension year and
48.1% attained sustained NEDA over years 2–5 (indi-
cating that most patients were free of relapses, 6-month
CDW, and new Gd-enhancing and T2 hyperintense
lesions; figure e-1B); in these patients with sustained
NEDA, BVL was also slowed (figure e-2).
Safety. Tables 1, 2, and e-2 summarize safety analyses
for alemtuzumab-treated patients over 5 years up to
the cutoff (1,986.7 patient-years). Overall incidences
and EAIR of AEs were lower than in the core study;
96.2% of AEs were mild to moderate in severity. The
EAIR of serious AEs was comparable to the core
study. When AEs were assessed by treatment course,
overall AE incidences for courses 3–5 were stable
compared with courses 1–2 (table e-3). No patients
discontinued from the extension study due to AEs.
Two deaths, both unrelated to alemtuzumab treat-
ment, were reported in the core study8; no deaths
occurred during the extension.
Incidences of IARs and serious IARs for courses
3–5 were reduced compared with courses 1–2
(table 2). When IARs were included in overall AE
counts, the EAIR was 871.3 in the core study and
201.3 in the extension; when IARs were removed, the
EAIR remained lower in the extension (195.0) than
in the core study (255.8; tables 1 and e-2). The most
commonly reported IARs in the extension were
headache, pyrexia, and rash.
Table 1 AEs through year 5 of the extension in patients treated with alemtuzumab 12 mg
EAIR per 100 patient-years (no. of
events)b
Incidence, core and extension studies (5 y), n (%)a
Core
study
(2 y)
Extension
study
(3 y)
Core and
extension
studies
(5 y)
Year 1
(n 5 435)
Year 2
(n 5 434)
Year 3
(n 5 412c)
Year 4
(n 5 387)
Year 5
(n 5 367)
Years 0–2
(n 5 435)
Years 3–5
(n 5 412)
Years 0–5
(n 5 435)
Any AE 412 (94.7) 402 (92.6) 343 (83.3) 316 (81.7) 284 (77.4) 871.3 201.3 703.6
Any AE excluding IARsd 373 (85.7) 379 (87.3) 341 (82.8) 312 (80.6) 284 (77.4) 255.8 195.0 213.8
AE leading to study drug
discontinuation
9 (2.1) 5 (1.2) 1 (0.2) 3 (0.8) 2 (0.5) 1.6 0.4 (5) 1.0
Any serious AE 55 (12.6) 43 (9.9) 39 (9.5) 53 (13.7) 36 (9.8) 11.1 10.5 9.9
Any serious AE excluding IARs 48 (11.0) 41 (9.4) 39 (9.5) 53 (13.7) 34 (9.3) 10.0 10.4 9.2
Deaths 0 2 (0.5) 0 0 0 0.2 (2) 0 0.1 (2)
Any infection event 275 (63.2) 268 (61.8) 206 (50.0) 195 (50.4) 162 (44.1) 89.0 54.1 65.2
Serious infections 9 (2.1) 8 (1.8) 5 (1.2) 9 (2.3) 7 (1.9) 1.9 1.6 1.7
Any thyroid disordere,f 31 (7.1) 40 (9.2) 68 (16.5) 23 (5.9) 12 (3.3) 8.8 14.1 11.3
Serious thyroid AEs 0 2 (0.5) 10 (2.4) 2 (0.5) 2 (0.5) 0.2 (2) 1.3 0.8 (16)
ITPe 1 (0.2) 3 (0.7) 2 (0.5) 7 (1.8) 1 (0.3) 0.5 (4) 0.9 (10) 0.7 (14)
Nephropathye 0 1 (0.2) 0 0 0 0.1 (1) 0 0.1 (1)
Malignant disease 0 2 (0.5) 2 (0.5) 0 0 0.2 (2) 0.2 (2) 0.2 (4)
Abbreviations: AE 5 adverse event; EAIR 5 exposure-adjusted incidence rate; IAR 5 infusion-associated reaction; ITP 5 immune thrombocytopenia.
a Percentage is based on number of patients having an AE in the reported year divided by the total number of patients followed up in that year.
b (Number of patients with a specific event divided by total exposure time among patients at risk of an initial occurrence of the event) 3 100. Events
occurring in ,1 per 100 patient-years include number of events in parentheses.
c In addition to the patients enrolled in the extension study, the safety analyses included a small number of core study patients (n 5 19) who did not enter
the extension but were evaluated for AEs temporarily after the initial 2-year period.
dAll patients with any AE, excluding those patients whose only AEs were IARs. IARs were any AE that occurred during the infusion or within 24 hours after
the end of the infusion.
e Includes first event by year of occurrence.
f Defined as any thyroid AE or abnormal thyroid-stimulating hormone level, with simultaneously abnormal free triiodothyronine (T3) or free thyroxine (T4) on
the same visit.
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Infection AE incidences and EAIRs declined from
the core study to the extension (tables 1 and e-2), and
incidences did not increase with successive alemtuzu-
mab courses (table e-3); 97.7% of infections in years
3–5 were mild to moderate. As in the core study, the
most common infections were nasopharyngitis, uri-
nary tract infection, and upper respiratory tract infec-
tion. Herpetic infections were predominantly
mucocutaneous and most frequent in the first month
after alemtuzumab treatment. Serious infection inci-
dences in the extension were stable compared with
the core study.
The most common autoimmune AEs were thy-
roid AEs (5-year incidence: 37.7%); incidences
peaked in year 3 (17.0%) compared with years 1
(5.1%) and 2 (8.8%), and declined in years 4
(5.4%) and 5 (3.5%). A similar incidence pattern
was observed for the more comprehensive classifica-
tion of thyroid disorders (thyroid AEs combined with
abnormal thyroid function test), peaking at year 3
and declining thereafter (tables 1 and e-2; 5-year inci-
dence: 40.0%). Serious thyroid AE incidences were
,2.5% during each year. Thirteen patients under-
went thyroidectomy during the extension, most of
whom were subsequently maintained on thyroxine.
Ten new cases of ITP were reported during the
extension (n 5 2, 7, and 1, in years 3, 4, and 5,
respectively). Cases were detected based on clinical
signs (e.g., presence of petechiae but no major hem-
orrhage) or low platelets from laboratory monitoring,
and responded to therapy including steroids and/or
IV immunoglobulin, or rituximab.
No new nephropathy cases developed during the
extension. During the core trial, as reported previ-
ously,8 one patient developed membranous glomeru-
lonephritis, with proteinuria, microhematuria, and
hypoalbuminemia, but normal serum creatinine.
Nephropathy persisted during the extension and 4
concomitant medications for nephrotic syndrome
were administered (furosemide, valsartan, metola-
zone, and oral potassium chloride). Serum creatinine
level remained normal.
Two malignancies (papillary thyroid microcarci-
noma and melanoma) were reported in years 3–5.
Over 5 years, a total of 4 malignancies were reported
(1 case of thyroid cancer and 1 case of basal cell
carcinoma occurred in the core study; EAIR of 0.2
per 100 patient-years).
EAIRs in the pooled alemtuzumab 12- and 24-mg
groups (596 patients) were similar to those for the
12-mg group (table e-4).
DISCUSSION Events that occur early in MS, includ-
ing subclinical inflammation, contribute to poten-
tially permanent disability later in the disease
course.10,11 Patients with disease activity while
Table 2 Infusion-associated reaction (IAR) events through year 5 in patients treated with alemtuzumab 12 mg
IARsb by course
Incidence, n (%)a
Core study Extension study
Patients receiving
initial 2 courses,
courses 1–2 (n 5 435)
Patients receiving
retreatment,
courses 3–5 (n 5 158)
Course 1
(n 5 435)
Course 2
(n 5 421)
Course 3
(n 5 158)
Course 4
(n 5 45)
Course 5
(n 5 6)
Any IAR 364 (83.7) 300 (71.3) 101 (63.9) 31 (68.9) 3 (50.0) 393 (90.3) 108 (68.4)
IAR events affecting >10% of
patients over courses 1–5
Headache 156 (35.9) 118 (28.0) 43 (27.2) 11 (24.4) 0 188 (43.2) 50 (31.6)
Rashc 163 (37.5) 72 (17.1) 17 (10.8) 5 (11.1) 1 (16.7) 181 (41.6) 19 (12.0)
Nausea 51 (11.7) 36 (8.6) 12 (7.6) 4 (8.9) 0 72 (16.6) 15 (9.5)
Pyrexia 43 (9.9) 41 (9.7) 18 (11.4) 5 (11.1) 1 (16.7) 69 (15.9) 21 (13.3)
Urticaria 57 (13.1) 24 (5.7) 7 (4.4) 4 (8.9) 0 64 (14.7) 10 (6.3)
Pruritusd 47 (10.8) 12 (2.9) 5 (3.2) 2 (4.4) 1 (16.7) 54 (12.4) 7 (4.4)
Insomnia 33 (7.6) 15 (3.6) 4 (2.5) 1 (2.2) 0 44 (10.1) 4 (2.5)
Flushing 28 (6.4) 13 (3.1) 8 (5.1) 5 (11.1) 1 (16.7) 34 (7.8) 14 (8.9)
Serious IARse 6 (1.4) 6 (1.4) 2 (1.3) 0 0 12 (2.8) 2 (1.3)
a Percentage is based on number of patients having an IAR in the reported course divided by total number of patients followed up for that course.
b IARs were any adverse event that occurred during the infusion or within 24 hours after the end of the infusion.
c Rash includes the preferred terms rash and rash generalized.
d Pruritus includes the preferred terms pruritus and pruritus generalized.
e The following serious IARs occurred in 2 patients each: pyrexia (course 1), urticaria (course 1). The following serious IARs occurred in 1 patient each: chest
discomfort (course 1), chest pain (course 1), cough (course 1), dyspnea (course 2), edema peripheral (course 2), hemoptysis (course 2), headache (course 3),
hypothyroidism (course 2), infusion-related reaction (course 2), nausea (course 2), noncardiac chest pain (course 2), postlumbar syndrome (course 3), status
migrainosus (course 2), trigeminal neuralgia (course 3), vomiting (course 2). No serious IARs occurred in courses 4 or 5.
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receiving modest-efficacy DMT may have clinical
exacerbations with adverse long-term implications.12–
14 In such patients, few data exist to inform the
decision between continuing their current therapy or
switching to more efficacious treatment,15–20 although
several studies have shown that timely switching to
high-efficacy DMTs reduces relapse rates and dis-
ability accumulation.12,13 Moreover, DMT switching
must be considered for patients who develop new risk
factors, resulting in a less favorable benefit:risk bal-
ance of the current therapy. The CARE-MS II trial
enrolled patients with disease activity during IFN-b
or glatiramer acetate treatment, and compared effi-
cacy and safety over 2 years of further modest-efficacy
DMT (SC IFN-b-1a) against switching to alemtu-
zumab. Here we describe long-term outcomes of
patients from the CARE-MS II alemtuzumab arm
who participated in an extension, with 5 total years of
follow-up.
Our results demonstrate that reductions in disease
activity and cerebral atrophy with alemtuzumab con-
tinue over 5 years. ARR remained low over 5 years,
and most patients had stable or improved EDSS
scores and were free of 6-month CDW; 43%
achieved 6-month CDI. The improvements in preex-
isting disability with alemtuzumab are noteworthy.
During years 3, 4, and 5, most patients had no clin-
ical or MRI lesion activity and were free of active le-
sions, and the majority of patients achieved NEDA;
about a quarter of this population with an inadequate
response to prior therapy met the more challenging
endpoint of sustained NEDA throughout the exten-
sion (years 3–5).
Cerebral atrophy occurs at a faster rate among pa-
tients with MS compared with healthy individuals
and correlates with poorer clinical outcomes, includ-
ing long-term physical and cognitive impairment.21–27
Therefore, slowing of brain atrophy has emerged as
a clinically relevant outcome for RRMS. Alemtuzu-
mab slowed annual BVL throughout years 3–5, and
cumulative BVL over 5 years in alemtuzumab-treated
patients was less than in patients who received core
study SC IFN-b-1a and then switched to alemtuzu-
mab in the extension (median BPF changes of
20.855% vs 21.044%, respectively).28 These find-
ings further support the long-term benefits of earlier
alemtuzumab treatment and may indicate potential
neuroprotective effects.
The continued efficacy of alemtuzumab during
the extension was accompanied by a safety profile that
was consistent with prior studies.6–8 As expected
based on phase 2 data,29 the incidence of autoim-
mune thyroid AEs peaked in year 3, declining there-
after. Incidences of other autoimmune AEs, including
ITP, were much lower. Malignancies remained infre-
quent over 5 years. Two papillary thyroid carcinomas
were discovered incidentally during imaging for thy-
roid dysfunction.30,31 It is unknown whether these
tumors would be characterized differently using
recent reclassification criteria.32 Overall, AEs
decreased over time after alemtuzumab treatment,
in contrast to some other DMTs, which are associated
with known risks that remain constant or increase
with chronic exposure to the drug.33–35 Monthly lab-
oratory monitoring and effective management of
potential AEs mitigate the risks of alemtuzumab to
maximize therapeutic benefit.
Limitations of our study include the potential for
bias due to open-label aspects of its design; however,
rater blinding was maintained for disability and imag-
ing assessments, and the results of those endpoints
were fully consistent with the observed relapse out-
comes and with those of the rater-blinded core phase
3 study. Although comparator therapy was not con-
tinued into the extension, so there is no control group
for the long-term data, the clinical and imaging ben-
efits observed with alemtuzumab during the exten-
sion were maintained or even improved compared
with the core study. This would not be expected if
treatment were ineffective, especially given that all pa-
tients had active RRMS on prior therapy before initi-
ation of alemtuzumab. Selection bias could arise as
participation in the extension was voluntary. How-
ever, the patient retention rate in our study
(.90%) was unusually high compared with exten-
sion studies of other MS DMTs (range 68%–
84%).36–38 Of potential relevance to maintaining such
a high retention rate is the fact that persisting efficacy
was achieved in the absence of continuous treatment,
which contrasts with the reported loss of efficacy fol-
lowing cessation of other MS therapies.39,40
Reducing clinically manifest MS disease activity
and altering the downward trajectory of MS-related
brain atrophy are critical to avoid potentially perma-
nent loss of function and a declining quality of life.
Our study reports long-term maintenance of alemtu-
zumab’s therapeutic effects on stringent clinical and
MRI lesion outcomes and brain atrophy. Risks
accompanying such beneficial effects may be miti-
gated effectively when patients and physicians are
vigilant to early symptoms and adhere to the safety
monitoring program. As efficacy was maintained
while the incidence of most AEs declined over time,
the evolving benefit–risk balance shifted favorably
over time. We suggest that alemtuzumab constitutes
a unique treatment approach that can provide durable
efficacy in the absence of continuous dosing, and with
manageable adverse effects.
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